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Abstract 
Background: Cushing’s syndrome is a severe condition with excess mortality 
and significant morbidity necessitating control of hypercortisolemia. There are 
few data documenting use of the steroidogenesis inhibitor metyrapone for this 
purpose. 
Objective: To assess the effectiveness of metyrapone in a contemporary 
series of patients with Cushing’s syndrome. 
Design: Retrospective, multicenter. 
Setting: Thirteen university hospitals. 
Patients: 195 patients with proven Cushing’s syndrome: 115 Cushing’s 
disease (CD), 37 ectopic ACTH (EAS); 43 ACTH-independent disease 
(Adrenocortical Cancer [ACC] 10; adrenal adenoma [AA] 30; ACTH-
independent adrenal hyperplasia (3) 
Measurements: Biochemical parameters of activity of Cushing’s syndrome: 
mean serum cortisol day curve (CDC) (target 150-300nmol/L); 09.00h serum 
cortisol; 24h-UFC. 
Results: 164/195 received metyrapone monotherapy. Mean age was 49.6 +/- 
15.7 years; mean duration of therapy 8 months (median 3 months, range 3 
days to 11.6 years). There were significant improvements on metyrapone - 
first evaluation to last review: CDC [91 patients, 722.9nmol/L (26.2μg/dl) vs. 
348.6nmol/L (12.6μg/dl), p<0001]; 09.00h cortisol [123 patients, 882.9nmol/L 
(32.0μg/dl) vs. 491.1nmol/L (17.8μg/dl), p<0.0001]; UFC [37 patients, 
1483nmol/24h (537μg/24h) vs. 452.6nmol/24h (164μg/24h), p=0.003]. Overall 
control at last review: 55%, 43%, 46% and 76% of patients who had CDCs, 
UFCs, 09.00h cortisol <331nmol/L (12.0μg/dl) and 09.00h cortisol 
<ULN/600nmol/L (21.7μg/dl). Median final dose: CD 1375mg; EAS 1500mg; 
benign adrenal disease 750mg; ACC 1250mg.  Adverse events occurred in 
25% of patients, mostly mild GI upset and dizziness, usually within 2 weeks of 
initiation or dose increase, all reversible. 
Conclusions: Metyrapone is effective therapy for short- and long-term control 
of hypercortisolemia in Cushing’s syndrome. 
Introduction 
Cushing’s syndrome (CS) is a severe condition with excess mortality and 
significant morbidity necessitating effective biochemical control (1). Where a 
cause amenable to surgical intervention is identified, surgery at a center with 
appropriate expertise is the optimum management.  Nevertheless, many 
patients need urgent control of severe or persisting hypercortisolemia. 
Options for medical treatment include steroidogenesis enzyme inhibitors 
suitable for all causes of CS (ketoconazole, metyrapone, mitotane), agents to 
suppress ACTH in Cushing’s disease (CD), such as dopamine agonists and 
pasireotide, and the glucocorticoid receptor antagonist, mifepristone (2,3).  
The modern use of ketoconazole has recently been reported in a multicenter 
French Study (4), although its availability in the United States has been 
restricted following an FDA safety warning for hepatotoxicity in 2013 (5,6), but 
it is widely available in Europe in 2015 (7). 
 
The cortisol-lowering effect of metyrapone was described as early as 1958 by 
Liddle and co-workers, with later reports confirming metyrapone as a potent 
inhibitor of the steroidogenesis enzyme 11β-hydroxylase (8,9). Since then, it 
has been used as a diagnostic test of adrenal reserve and to treat the 
hypercortisolism of CS.  Despite its widespread use, data on metyrapone are 
scarce, with the largest study to date (including 91 patients) being published 
over 25 years ago (10).  Here, we have assessed the effectiveness of 
metyrapone therapy in a contemporary series of patients with CS, by 
performing a retrospective study of patients treated in the UK. 
Methods 
A multicenter, retrospective study was performed across thirteen University 
Hospital centers in England and Wales, members of the UK Endocrine 
Neoplasia Collaboration.  Patients treated with metyrapone were identified 
through pharmacy records and electronic databases. Patients with a 
diagnosis of CS and treated with metyrapone between 1997 and 2013 were 
included. 
 
The same proforma was used in all centers to record anonymized data.  Data 
were gathered from case records and electronic record systems.  Baseline, 
demographic and safety data, the indication for treatment and dose of 
metyrapone therapy, any therapeutic intervention and any recorded adverse 
events were documented. Monitoring tests included early morning (09.00h) 
serum cortisol, 24-hour urinary free cortisol (UFC), serum potassium, plasma 
ACTH and serum cortisol ‘day-curves’ (CDC). In CDCs multiple samples for 
serum cortisol are collected across the day with the mean calculated (11). All 
tests performed during the monitoring period were collected and analyzed. All 
centers used immunoassay-based cortisol assays.  
 
Patients were treated either with a dose titration regimen i.e. metyrapone 
dose was up-titrated according to response to achieve a biochemical target 
for cortisol, or a block-and-replace regimen where the dose of metyrapone 
was quickly up-titrated to achieve blockade of cortisol synthesis and a 
replacement dose of glucocorticoid was added to provide background 
physiological levels. 
Biochemical targets for treatment (eucortisolemia) were defined as a mean 
CDC value of 150-300nmol/l (10.9μg/dl), which has been shown to equate to 
a normal cortisol production rate as assessed by stable isotopic methodology 
(11), a UFC level below the upper limit of normal (ULN) for the assay used or 
a 09.00h serum cortisol within target. Although 09.00h serum cortisol is 
occasionally being used as a sole test for evaluating patients’ response to 
treatment there is currently no standardized agreement for what values of this 
test represent appropriate control. Two different levels of target 09.00h 
cortisol were therefore assessed; (i) below the upper limit of normal for the 
assay used, or less than 600nmol/l (21.7μg/dl) if the ULN was higher than this 
value, and (ii), a recommended value of 331nmol (12.0μg/dl) (12). Cortisol 
levels were reported in nmol/L and divided by 27.59 to calculate the 
equivalent value in μg/dl. There was a wide range of UFC assays used with 
variable reference range of normal values; therefore UFC values were 
converted to multiples of the upper limit of normal (ULN) for the assay and this 
value was used for statistical comparisons. Patients with sufficient monitoring 
data (i.e. at least one test as described above repeated at least twice during 
the study period) were included in the efficacy analysis. For the efficacy 
analyses we compared the mean values at each monitoring test (CDC, 
09.00h serum cortisol, UFC) before treatment to (i) the mean values on the 
last review on treatment (diagnosis vs. last review), and (ii) the mean of all 
tests performed in all patients during treatment (diagnosis vs. treatment), 
unless otherwise stated. The change of the biochemical markers between (i) 
baseline (at diagnosis/ pre-treatment) and the last review on treatment for 
09.00h cortisol, and (ii) the first and the last biochemical review for CDCs 
(CDCs were not routinely performed prior to initiation of treatment) on 
treatment was also analyzed.  
Statistical analysis was performed using the two-tailed Student’s t test 
(GraphPad prism 6.0, GraphPad Software Inc., La Jolla, USA). Except where 
stated, values given are means +/- standard deviations. A p-value of less than 
0.05 was considered significant. The study was approved as an institutional 
case notes review at each participating center.  
 
Results 
Baseline characteristics 
One hundred and ninety-five patients were treated with metyrapone across 
the 13 centers. The majority of patients had CD (115 patients, 37 
macroadenoma) with the remainder having ectopic ACTH syndrome (EAS, 
37), adrenocortical carcinoma (ACC, 10), and benign adrenal disease [30 
adrenal adenoma (AA), ACTH-independent macronodular adrenal hyperplasia 
(2) and primary pigmented nodular adrenal hyperplasia (1)] (Table 1). There 
was a female predominance in all causes of CS except EAS (female patients: 
74% CD, 49% EAS, 86% AA, 80% ACC). Patients were treated with 
metyrapone between 1997 and 2013 (83% between 2007-2013). The average 
duration of treatment was eight months (median 3 months, range 3 days to 
11.6 years).  At initiation of treatment there was a wide age distribution, with 
76% of patients aged 30-69 years (age range 1-81, median age 48, average 
age 49.6 +/- 15.7 years), and 32% of patients (n=63) were women in the 
reproductive ages 18 to 45 (Figure 1).  Co-morbidities at presentation 
included hypertension (64.6%) and diabetes mellitus (35.3%). For patients 
with CD, baseline contrast-enhanced pituitary MRI was positive in all patients 
with a macroadenoma and in 53 out of 72 (73%) patients with a 
microadenoma. 
 
The main indication for metyrapone therapy was the control of severe 
symptoms of CS (CD 58%, EAS 77%, benign adrenal disease 44% and ACC 
80%). Medical therapy was initiated as part of routine local practice in 8 out of 
13 centers for the management of patients after diagnosis and prior to 
definitive therapy (e.g. surgery) regardless of the level of hypercortisolemia in 
a smaller number of patients (CD 25%, EAS 11%, benign adrenal disease 
37%, ACC 0%). Delay in definitive treatment for CS (either due to medical 
reasons or requested by the patient) was a reason for starting medical 
therapy in 19% of patients. 25/195 patients (12.8%) received only cortisol-
lowering treatment for their CS because of either inconclusive surgical target, 
palliation of aggressive malignancy (ACC or lung carcinoma), patients’ own 
preference, or high surgical risk. 
 
Biochemical changes during metyrapone treatment 
Monitoring data during metyrapone therapy were available for 193 patients. 
The frequency of the monitoring visits was variable with some centers opting 
for inpatient tests at the introduction of treatment and other centers using 
outpatient monitoring every few weeks. 81% of patients were treated with 
dose titration and 19% with ‘block-and-replace’.  
 Metyrapone monotherapy 
One hundred and sixty four patients received metyrapone monotherapy and 
all monitoring tests showed significant improvement during treatment; CDC 
[91 patients, mean at diagnosis 722.9nmol/L (26.2μg/dl) vs. during treatment 
396.4nmol/L (14.4μg/dl), p<0.0001, last review 348.6nmol/L (12.6μg/dl), 
p<0001], 09.00h cortisol [123 patients, mean at diagnosis 882.9nmol/L 
(32.0μg/dl) vs. treatment 527.8nmol/L (19.1μg/dl), p<0.0001, last review 
491.1nmol/L (17.8μg/dl), p<0.0001], UFC [37 patients, mean at diagnosis 
1483nmol/24h (537μg/24h) vs. treatment 1070nmol/24h (388μg/24h), 
p=0.588, last review 452.6nmol/24h (164μg/24h), p=0.003], UFC:ULN [mean 
at diagnosis 7.2 vs. treatment 5.4, p=0.556, last review 2.5 p=0.020]. At the 
last review, 55%, 43%, 46% and 76% of patients who had CDCs, UFCs, 
09.00h cortisol <331nmol/L (12.0μg/dl) and 09.00h cortisol< ULN/600nmol/L 
(21.7μg/dl) were controlled.  
 
Ninety-one patients were monitored with cortisol ‘day-curves’ during 
treatment; 47/91 (52%) patients achieved a mean CDC < 300nmol/L 
(10.9μg/dl) during treatment (i.e. normalized cortisol target) and 81% of those 
who did not normalize had an improvement between the first and the last 
assessment on treatment (Figure 2a). A total of 123 patients had 09.00h 
serum cortisol levels monitored; during treatment 83% (102/ 123) had a 
09.00h serum cortisol bellow 600nmol/L (21.7μg/dl) or the ULN for the assay 
used and 56% (69/ 123) had a 09.00h level bellow 331nmol/L (12.0μg/dl) with 
86% of patients showing an improvement in cortisol levels (mean 
improvement 566nmol/L, median 467nmol/L) even if these biochemical 
targets were not achieved (Figure 2b).  
 
Effectiveness of metyrapone monotherapy before surgery 
The majority (124/164) of patients treated with metyrapone monotherapy 
received treatment before any surgical intervention (CD 81, EAS 11, benign 
adrenal disease 25, ACC 7) for an average of 4.0 months.  Monitoring data on 
CDCs were available in 70 patients, 09.00h serum cortisol in 82 and UFC in 
25 patients. There was a significant improvement in the biochemical targets 
during metyrapone therapy: 09.00h serum cortisol [mean at diagnosis 
779.7nmol/L (28.3μg/dl) vs. treatment 508.0nmol/L (18.4μg/dl) (p<0.0001), 
last review 495.6nmol/L (18.0μg/dl)  (p<0.0001)]; mean CDC [diagnosis 691.5 
nmol/L (25.1μg/dl) vs. treatment 407.7nmol/L (14.8μg/dl) (p<0.0001), last 
review 351.5nmol/L (12.7μg/dl)  (p<0.0001)]; UFC [mean UFC to ULN ratio at 
diagnosis 6.4 vs. treatment 5.5 (p=0.553), last review 2.9, (p=0.014)]. At the 
last review, 50%, 35%, 40% or 72% of patients who had CDCs, UFCs, 09.00h 
cortisol <331nmol/L (12μg/dl) or 09.00h cortisol< ULN/600nmol/L (21.7μg/dl) 
were controlled (for dose see Table 2). 
 
At the time of the first normalization, 91% were treated with dose titration and 
9% with block-and-replace.  In ACTH-dependent disease plasma ACTH levels 
were measured too sporadically to allow meaningful analysis.  10/18 (56%) 
patients who did not achieve a biochemical target also had a reduction of 
cortisol levels.  
 
Metyrapone monotherapy as secondary treatment 
Thirty-one patients (29 CD, 1 EAS, 1 benign adrenal disease) received 
metyrapone as secondary treatment following either surgery (21) or pituitary 
radiotherapy (17): 21/31 as monotherapy; 10/31 as combination therapy. Of 
the patients who received metyrapone following primary surgery, 19 had 
pituitary surgery for CD (9 had a macroadenoma); one had a pancreatectomy 
for a neuroendocrine tumor; and one a repeat adrenalectomy for an 
incomplete excision of an adrenal adenoma. Of the patients with CD 7/19 also 
received pituitary radiotherapy. For the patients on monotherapy (n=21), the 
mean starting dose of metyrapone was 1300mg (Table 2). Patients were 
treated for an average of 17.1 months. At the last review, 76%, 78% or 94% of 
patients who had CDCs, 09.00h cortisol <331nmol/L (12μg/dl) or 09.00h 
cortisol <ULN/600nmol/L (21.7μg/dl) were controlled. At normalization 35% 
(6/17) of patients were treated with block-and-replace, and 65% (11/17) with 
dose titration.  All biochemical tests improved during treatment; mean CDC 
[mean at diagnosis 478.5nmol/L (17.3μg/dl) vs. treatment 311.0nmol/L 
(11.3μg/dl), p=0.001, last review 248.9nmol/L (9.0μg/dl), p=0.001], 09.00h 
cortisol [mean at diagnosis 659.6nmol/L (23.9μg/dl) vs. treatment 361.3nmol/L 
(13.1μg/dl), p=0.0001, last review 281.3nmol/L (10.2μg/dl), p=0.002]. Only 
four patients had UFCs during treatment, therefore the change in UFC for this 
group of patients was not analyzed. 
 
Long-term treatment with metyrapone monotherapy 
Monitoring data were available on 38 patients who received metyrapone 
monotherapy for longer than 6 months. The average duration of treatment 
was 18.6 months and 6 patients had block-and-replace at some point during 
their treatment. Biochemical tests improved during treatment; mean CDC [at 
diagnosis 451.4nmol/L (16.4μg/dl) vs. treatment 339.5nmol/L(12.3μg/dl) 
p=0.07, last review 366.2nmol/L (13.3μg/dl), p=0.35], 09.00h cortisol 
[diagnosis 734.2nmol/L (26.6μg/dl) vs. treatment 428.2nmol/L (15.5μg/dl), 
p<0.0001, last review 384.5nmol/L (13.9μg/dl), p<0.0001 ]. Overall, 
eucortisolemia was achieved in 72% (18/25) of patients who had CDCs, 77% 
(24/31) and 94% (29/31) of patients who had 09.00h cortisols (based on 
<331nmol/L or <ULN/600nmol/L cut-offs) or 64% (9/14) of patients who had 
UFCs. 
 
Starting and final dose (Table 2) 
Mean, median and range of doses on metyrapone monotherapy at the 
initiation of treatment and at final review are shown in Table 2. On ‘block-and-
replace’ the starting dose of metyrapone was higher (mean dose 1432mg vs. 
939.2mg, p<0.0001).  There were, however, no significant differences in the 
mean 09.00h serum cortisol levels during treatment or at the last review in the 
two groups [block-and-replace group during treatment 461.2nmol/L 
(16.7μg/dl) vs. dose titration group 507.8nmol/L (18.4μg/dl), p=0.50, last 
review 510.8nmol/L (18.5μg/dl) vs. 376.3nmol/L (13.6μg/dl), p=0.26]. 
 
Combination treatment 
Twenty-nine patients were treated with a combination of metyrapone and 
other cortisol-lowering medication (mainly ketoconazole or mitotane, 7 
patients had combination treatment from the start of therapy, whilst in 22 
combination therapy was instigated after initial treatment with metyrapone). 
The CDC or 09.00h serum cortisol levels at diagnosis were not significantly 
different in the patients treated with combination compared with the patients 
treated with metyrapone monotherapy [CDC combination 830.8nmol/L 
(30.1μg/dl) vs. monotherapy 722.9nmol/L (26.2μg/dl), p=0.558, 09.00h 
cortisol, combination 1149nmol/L (41.6μg/dl), vs. monotherapy 882.9nmol/L 
(32.0μg/dl) p=0.077]. There was a significant improvement in monitoring tests 
during treatment [CDC diagnosis 830.8nmol/L (30.1μg/dl) vs. treatment 
314.2nmol/L (11.4μg/dl), p<0.0001, last review 278.7nmol/L (10.1μg/dl), 
p<0.0001. 09.00h cortisol diagnosis 1149nmol/L (41.6μg/dl) vs. treatment 
522.9nmol/L (19.0μg/dl), p<0.0001, last review 471.9nmol/L (17.1μg/dl), 
p=0.003]. Only three patients on combination therapy had UFC monitoring, 
precluding analysis. At the last review, 47%, 52% or 75% of patients who had 
CDCs, 09.00h cortisol <331nmol/L (12μg/dl) or 09.00h cortisol 
<ULN/600nmol/L (21.7μg/dl) were controlled. Patients who at the last review 
were controlled on a dose titration regimen based on CDCs and UFCs 
received 1850mg mean total daily dose (median 1500mg, range 750-6000mg). 
No subgroup analysis for efficacy was performed for this group due to small 
numbers.  
 
Safety considerations 
Side effects were noted in 48/195 patients (25%): 88% were managed as 
outpatients, whereas 12% (7/57 events) required either admission for 
evaluation or prolongation of a current admission.  The rate of adverse events 
in patients on therapy for >6months was 11% (4/38 patients). There were no 
pregnant women, and no deaths recorded due to an adverse event.  The 
average dose of metyrapone at the time of an adverse event was 1600mg. 
Gastrointestinal upset (23%) and hypoadrenalism (7% - symptoms of 
dizziness, hypotension, with biochemical confirmation) were the most 
common side effects. Most adverse events (39/56) occurred within 15 days of 
initiation of metyrapone or after a dose increase. Gastrointestinal upset and 
dizziness were the main reasons for discontinuing treatment. Patients with 
confirmed hypoadrenalism were managed either by addition of glucocorticoid 
(regimen change to a block-and-replace) or temporary cover with 
glucocorticoid and simultaneous reduction of metyrapone dose. In 15% of 
cases the metyrapone dose was reduced.  In 12 cases (23%) metyrapone 
was withdrawn temporarily or permanently, with 11/12 showing full resolution, 
and in one symptoms continued but became less severe - muscle aches at 
presentation worsened during metyrapone therapy but returned to pre-
treatment levels after drug withdrawal. Symptoms of hyperandrogenism were 
not frequent; hirsutism was not reported and there was only one case of 
worsening acne during treatment. Similarly edema was only reported in one 
case but the causative drug was thought to be a calcium channel blocker. 
Hypoglycemia was reported in three patients on diabetic medications and was 
associated with improvement of hypercortisolism. 
 
Potassium levels were monitored and actively treated at presentation and 
during therapy. In 138 patients on metyrapone monotherapy, with no other 
treatment interventions for their CS, mean potassium levels increased from 
3.68nmol/L to 3.90nmol/L (p=0.003) during treatment (Figure 3). 
 Discussion  
We report the effectiveness of metyrapone in clinical practice for the treatment 
of CS.  To our knowledge this is the largest study of metyrapone use as either 
monotherapy or metyrapone in combination with other cortisol-lowering 
medications.  Overall more than 80% of patients showed an improvement in 
levels of circulating cortisol with over 50% achieving biochemical 
eucortisolemia when on monotherapy when assessed by the stringent 
criterion of control on a CDC.  It is likely that additional therapies were added 
because of the severity of disease and clinician preference, but the 
retrospective and multicenter nature of our study precludes a formal 
assessment of this. Furthermore, our data support that metyrapone 
monotherapy is an effective treatment for hypercortisolemia either before or 
after surgical intervention to the primary cause of CS. 
 
Metyrapone is widely used in CS in the UK and other countries but less so in 
the USA. To date, the efficacy of metyrapone in reducing cortisol levels in CS 
has been described in case reports and small case series (13-16), with the 
largest series reported 25 years ago by Verhelst et al (10). In this single 
center experience, metyrapone was effective in reducing cortisol levels in 
75% of 91 patients with CD, EAS and ACC based on a mean CDC level 
<400nmol/L that is higher than the more stringent <300nmol/L level that we 
used in this study. Most patients in the Verhelst study received a short course 
of metyrapone except for 24 patients who had metyrapone for a median of 27 
months following radiotherapy to the pituitary gland. Smaller studies have 
reported the efficacy of metyrapone in patients with CD undergoing 
radiotherapy (13-15) and EAS (17). Overall, in 200 cases of metyrapone 
monotherapy published in the English literature, biochemical control was 
achieved in 75% (18). We report similar efficacy. It is of note, however, that 
the majority of patients with CD in our study here were not treated in 
conjunction with pituitary radiotherapy, and there did not appear to be 
evidence of an escape of control phenomenon, although we cannot comment 
on plasma ACTH levels during monitoring. 
 
Ketoconazole, an antifungal agent and inhibitor of adrenal steroidogenesis, 
has also been widely used as a cortisol-lowering agent in CS. In the largest 
report to date, Castinetti et al reported biochemical control in 50% of patients 
with CS treated with ketoconazole monotherapy with biochemical 
improvement in 75% and evidence of regression of clinical features in up to 
60% (4). Overall, in 456 published cases treated with ketoconazole 
monotherapy, 60% achieved control (18).  Combination treatment with 
metyrapone and ketoconazole is commonly used (19), especially for the rapid 
control of hypercortisolism prior to definite treatment. In 22 patients with 
severe hypercortisolism due to EAS (n=14) and ACC (n=8), combination 
treatment of metyrapone and ketoconazole dramatically improved UFC levels 
within a month of treatment, while half of the patients also started mitotane 
during this time (20). Kamenicky et al used a triple-medication protocol with 
simultaneous administration of ketoconazole, metyrapone and mitotane in 11 
patients with hypercortisolism and life-threatening complications as an 
alternative to bilateral adrenalectomy; all patients showed rapid clinical and 
biochemical improvement (21). In both studies, the initial biochemical control 
is mainly due to the combination of ketoconazole and metyrapone as the 
onset of action of mitotane is usually delayed by several weeks due to 
accumulation in adipose tissue (22). In one of the few prospective studies of 
medical treatment of CD, Feelders et al used a stepwise approach to treat 17 
patients with CD with a combination of pituitary and adrenal-acting agents. 
Patients were initially treated with the somatostatin analog pasireotide, 
followed by cabergoline, and ketoconazole was later introduced if biochemical 
control was suboptimal. Nine out of 17 patients normalized with pasireotide/ 
cabergoline and ketoconazole induced biochemical control in 6/8 remaining 
patients (75%) within 20 days of treatment (23).  
 
Metyrapone increases cortisol metabolites in the serum and urine due to the 
predominant inhibition of 11β-hydroxylase, and to a lesser extent the other 
steroidogenesis enzymes (10,24). In particular, 11-deoxycortisol levels may 
become profoundly elevated in patients on metyrapone therapy, especially in 
patients with CD (25,26). 11-deoxycortisol is structurally very similar to cortisol 
and may cross-react with cortisol immunoassays resulting in an 
overestimation of serum cortisol values in patients on metyrapone (26,27). 
The importance of this is underscored by the fact that symptoms of adrenal 
insufficiency may overlap those of side effects of metyrapone. Thus, cortisol 
estimation by more accurate methods such as mass spectrometry is 
preferable and should be used where available (28). Moreover, it is likely that 
our data may underestimate the efficacy of metyrapone therapy when 
assessing serum measurements of cortisol as the cross-reactivity in 
immunoassays results in approximate 20% elevated bias (25). 
 
Hypokalemia has been described as a potential serious complication of 
metyrapone therapy (24,29) due to the increase in steroid precursors with 
mineralocorticoid activity (11-deoxycorticosterone). Our data suggest 
clinicians using metyrapone are well aware of the importance of monitoring 
and managing serum potassium levels since we found that these increase 
significantly with supportive measures during treatment.  It is important to 
stress, however, that such active monitoring is required, as hypokalemia is 
also a potentially harmful feature of CS. The most common adverse effects 
observed were mild gastrointestinal symptoms and hypoadrenalism, the latter 
a positive response to treatment provided that it is recognized and managed 
early. Patients on long-term treatment are more likely those who tolerate 
metyrapone well, therefore the rate of adverse events was favorable in this 
subgroup. Interestingly, hirsutism was not reported. 
 
This study carries the limitations imposed by its retrospective design. 
Furthermore, there is currently no standardized monitoring and dosing 
regimen for patients on metyrapone therapy. The monitoring of 
hypercortisolemia in patients with CS on medical treatment is important to 
ensure that patients are treated with the correct dose and that 
hypoadrenalism, if present, is recognized early; measurement of serum 
cortisol allows this. Even though the study was conducted in University 
centers with significant expertise in the management of CS, the choice of 
biochemical monitoring test and frequency of monitoring varied. This has 
affected the uniformity of the data presented. During the period of the study 
the common clinical practice was to aim for a 09.00h cortisol bellow the upper 
limit of normal for the assay used or less than 600nmol/L. Any results above 
these levels would prompt up-titration of the dose or addition of a second 
agent.  Therefore we have reported these cut-offs as the criteria for 
normalization of hypercortisolemia. More stringent 09.00h serum cortisol 
levels to define control have been proposed recently (12), with suggested 
values below 331 nmol/L (12μg/dL). It is not possible to know whether 
clinicians would have up-titrated the dose of metyrapone had this criterion 
been used, and therefore we can only speculate that the overall control when 
using this criterion might have been better if applied in practice.  
 
In conclusion, our data show that metyrapone is effective and safe in treating 
hypercortisolemia in patients with Cushing's syndrome. 
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Figure legends 
 
Figure 1 
Age of patients at initiation of metyrapone therapy and diagnosis of 
Cushing’s syndrome 
 
 
Figure 2 
Mean serum cortisol day curve (CDC) and 09.00h serum cortisol levels 
during treatment with metyrapone monotherapy.  
 
a), Change in mean CDC in 91 patients treated with metyrapone monotherapy 
between the 1st review following initiation of metyrapone and the last review 
on treatment: 52% (47/91) patients achieved biochemical normalization, 89% 
showed an improvement).  
b), Change in the pre-treatment 09.00h cortisol level in 123 patients treated 
with metyrapone monotherapy and the last review on treatment: 86% showed 
an improvement; 102 (83%) patients had a 09.00h serum cortisol value below 
the ULN for the assay used or 600nmol/L (whichever was lowest) and 69 
(56%) had a 09.00h level<331nmol/L. 
 
 
Figure 3 
Potassium levels before and during metyrapone monotherapy in 138 
patients.  
 
 
 
Table 1 Baseline patient characteristics 
Etiology No of patients Female/ Male Average age at diagnosis 
(years) 
Average age at metyrapone 
onset (years) 
Cushing’s disease  
   Macroadenoma  
   Microadenoma   
115 
37 
77 
85/30 45.9 47.4 
Ectopic ACTH syndrome  37 18/19 52.6 52.9 
Benign Adrenal Disease   
   Adrenal adenoma 
   AIMH    
   PPNAD   
33 
30 
2 
1 
27/5 
 
26/4 
1/1 
50.3 51.2 
Adrenocortical Carcinoma  10 8/2 56.0 56.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Total daily dosage of metyrapone for patients treated with a dose titration regimen  
 *Starting dose (mg) *Final dose (mg) 
Metyrapone monotherapy (n=164) 
CD (n=96) 
EAS (n=27) 
Benign adrenal disease (n=31) 
ACC (n=10) 
 
1040, 750, 250-3750 
1020, 750, 250-3000 
1260, 1000, 500-3750 
820, 1000, 250-2250 
1230, 1500, 750-2000 
1425/ 1500/ 500-4000 
1380/ 1375/ 500-3500 
1990/ 1500/ 500-3750 
1210/ 750/ 500-4000  
1190/ 1250/ 750-1500 
Pre-surgery (n=124) 
CD (n=81) 
EAS (n=11) 
Benign adrenal disease (n=25) 
ACC (n=7) 
 
1000, 750, 500-2250 
980, 750, 500-2250 
1200, 1500, 500-2000 
880, 750, 500-2250 
1250, 1500, 750-2000 
1440, 1500, 500-4000 
1400, 1500, 500-3500 
2120, 2250, 500-3750 
1230, 1000, 500-4000 
1080, 1000, 750-1500 
Secondary treatment (n=25) 
 
1300, 1125, 500-3000 1400, 1500, 500-2250 
Long-term treatment (>6months) (n=38) 940, 750, 500-3000 1560, 1500, 500-4000 
*given in 2-4 divided doses; mean/ median/ range 
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